An experimental drug for severe sepsis from AstraZeneca and BTG failed to help patients in a crucial mid-stage clinical trial and its development will now be halted, terminating pharma deals between AstraZeneca and BTG.
The pharma deals termination news is a blow for both companies’ drug pipelines, although the development of CytoFab, or AZD9773, was always viewed by analysts as risky.
For AstraZeneca, the news is a further blow to confidence in its research capabilities, following a series of earlier setbacks that had already narrowed its chances of finding new medicines to replace those going off patent.
In the light of the clinical trial data, AstraZeneca has decided to halt any further development of the product by terminating all the signed pharma deals and is handing the asset back to BTG, which has no plans to develop it further.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity